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Abstract
Aims/hypothesis Patients diagnosed with type 1 or type 2 di-
abetes have elevated levels of coagulation factor VIIa (FVIIa)
and its receptor tissue factor (TF) in their bloodstream. This
may affect the fate of the beta cells. We aimed to study the
effects of TF/FVIIa signalling on cytokine-induced beta cell
death and islet function in vitro.
Methods Human pancreatic islets and MIN-6 beta cells were
used to study TF mRNA and protein expression using real-
time PCR, immunoblotting and flow cytometry. The effects of
TF/FVIIa on cytokine-induced beta cell death were studied in
MIN-6 cells and human pancreatic islets using cell-death
ELISA and propidium iodide and cleaved caspase-3 staining.
Effects of TF/FVIIa on the phosphorylation of p38, extracel-
lular signal-regulated kinase and c-Jun N-terminal kinase
(JNK) were investigated by immunoblotting. Glucose-
stimulated insulin secretion (GSIS) from human islets was
measured with an insulin ELISA.
Results A combination of the cytokines IL-1β, TNF-α and
IFN-γ induced TF expression in human pancreatic islets and
in beta cells. TF/FVIIa did not affect basal beta cell death but,
independently of downstream coagulation activity, augmented
beta cell death in response to cytokines. The effect of TF/
FVIIa on cytokine-induced beta cell death was found to be
dependent on the stress kinase JNK, since FVIIa addition
potentiated cytokine-induced JNK activation and JNK inhibi-
tion abolished the effect of TF/FVIIa on cytokine-induced
beta cell death. Moreover, TF/FVIIa signalling resulted in
inhibition of GSIS from human pancreatic islets.
Conclusions/interpretation These results indicate that TF/
FVIIa signalling has a negative effect on beta cell function
and promotes beta cell death in response to cytokines.
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Abbreviations
ERK Extracellular signal-regulated kinase
FVIIa Coagulation factor VIIa
FXa Coagulation factor Xa
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
GSIS Glucose-stimulated insulin secretion
IL-1 Ra IL-1 receptor antagonist
JNK c-Jun N-terminal kinase
KRBH Krebs-Ringer bicarbonate HEPES buffer
LPS Lipopolysaccharide
MAPK Mitogen-activated protein kinase
NF-κβ Nuclear factor κ-light-chain-enhancer of
activated B cells
PAR-2 Protease-activated receptor 2
PI Propidium iodide
RPLP0 Ribosomal protein large, P0
siRNA Small interfering RNA
TF Tissue factor
Introduction
Type 1 and type 2 diabetes are characterised by progressive
loss and failure of the insulin-producing beta cells. In type 1
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diabetes, the loss of beta cells is thought to result from de-
struction of the beta cells located within the pancreatic islets of
Langerhans [1]. Upon activation, immune cells release pro-
inflammatory cytokines, such as IL-1β, TNF-α and IFN-γ,
believed to facilitate the dysfunction and death of beta cells
[1]. Beta cell death also contributes to type 2 diabetes, al-
though the pathogenesis is more variable and involves beta
cell death or failure and peripheral insulin resistance [2, 3].
Tissue factor (TF) is a transmembrane protein considered
to be the main regulator of haemostasis and thrombosis. TF
has mostly been studied for its role in blood clotting where,
after vascular injury or certain disease states, it binds coagu-
lation factor VIIa (FVIIa) and initiates the coagulation cascade
[4]. Beyond promoting blood clotting, TF/FVIIa can, via in-
tracellular signalling, contribute to processes such as tumour
growth and inflammation [4–6]. Islets and beta cells express
TF under normal conditions [7, 8] and islet TF has been stud-
ied in the field of islet transplantation, wherein TF coagulant
activity promotes clot formation, leading to islet cell death
after transplantation [8, 9]. Since diabetic patients show in-
creased plasma levels of TF and FVIIa, it is likely that the beta
cells of these individuals are subjected to TF/FVIIa signalling
[10–15]. However, the outcome of TF/FVIIa signalling on the
viability and function of beta cells has not been studied before.
In the present study, we provide evidence that TF/FVIIa sig-
nalling, independently from coagulation, impairs pancreatic
islet function and augments beta cell death in response to
cytokines.
Methods
Reagents CMRL 1066, DMEM, FCS, Trizol, Lipofectamine
RNAiMAX, Taqman probes and oligoDT primers were from
Life Technologies, Carlsbad, CA, USA. Hirudin, coagulation
factor Xa (Fxa) and Hoechst stain (33258) were from Sigma-
Aldrich, St Louis, MO, USA. Cytokines and IL-1 receptor
antagonist (IL-1 Ra) were from R&D systems, Minneapolis,
MN, USA. Cell Death Detection ELISAPLUS was from
Roche, Basel, Switzerland. Human and murine FVIIa were
kind gifts from L. C. Petersen (Novo Nordisk, Bagsvaerd,
Denmark). Small interfering RNAs (siRNAs) were fromTher-
mo scientific, Waltham, MA, USA. Insulin ELISA was from
Mercodia, Uppsala, Sweden. SB203580, PD98059 and
SP600125 were from Tocris Bioscience, Bristol, UK. The
following antibodies (Ab) were from Cell Signaling Technol-
ogy, Danvers, MA, USA: rabbit phosphorylated extracellular
signal-regulated kinase (phospho-ERK) (no. 4370), rabbit
phosphorylated c-Jun N-terminal kinase (phospho-JNK) (no.
4668), rabbit phospho-p38 (no. 4631), mouse ERK (no.
9107), mouse JNK (no. 3708), mouse p38 (no. 9217), rabbit
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (no.
2118) and rabbit cleaved caspase-3 (no. 9661). Rabbit TF
Ab (Ref. 4515) was from Sekisui Diagnostics, Lexington,
MA, USA. Guinea pig insulin Ab (Ab7842) was fromAbcam,
Cambridge, UK. Mouse TFAb (clone TF9-10H10) was from
AbD Serotec, Kiddlington, UK. Goat TF Ab (no. AF3178)
and goat IgG (no. AB-108-C) were from R&D systems. Rab-
bit TF Ab (no. N1C3) was from GeneTex, Irvine, CA, USA.
Islets and cells Human islets were provided by the Uppsala
facility for the isolation of human islets. After isolation, the
islets were cultured free-floating in Sterilin dishes in CMRL
1066 medium supplemented with 10% FCS, L-glutamine,
benzylpenicillin and streptomycin. Glucose responsive MIN-
6 cells were a kind gift from O. Idevall at the Department of
Medical Cell Biology, Uppsala University, Sweden. Before
use, cells tested negative for mycoplasma contamination using
MycoSEQ Mycoplasma Detection Kit (Life Technologies).
MIN-6 cells (passages 20–30) were grown inDMEMmedium
supplemented as above with the addition of 70 μmol/l
β-mercaptoethanol. Islets and cells were cultured in a humid-
ified chamber at 37°C and 5% CO2.
mRNA analysis Real-time quantitative PCR analyses of TF
(also known as F3) and the gene encoding ribosomal protein,
large, P0 (RPLP0) were performed on cDNA from oligoDT
converted total RNA extracted by Trizol according to standard
protocols.
FVIIa and cytokines FVIIa activity was validated by mea-
suring TF/FVIIa specific upregulation of IL8 mRNA in
MDA-MB-231 cells [16]. A concentration of 10 or 50 nmol/
l was used to achieve maximal activation of TF/FVIIa signal-
ling [16, 17]. Cells were stimulated with IL-1β (50 U/ml),
TNF-α (1,000 U/ml) and IFN-γ (1,000 U/ml) individually
or combined into a cytokine mixture. FVIIa was present dur-
ing cytokine exposure and culture media was changed and
fresh cytokines and FVIIa added every 24 h.
TF cell surface expression Cells were incubated with
10 μg/ml mouse TF Ab (no. AF3178) or normal 10 μg goat
IgG control (no. AB-108-C) for 1 h at room temperature and
then washed in PBS containing 1% (wt/vol.) BSA. The cells
were then incubated with Alexa Fluor 488 donkey anti-goat
secondary antibody (1/800 dilution) for 30 min at room tem-
perature before being analysed using a flow cytometer.
Transfections Cells were transfected using Lipofectamine
RNAiMAXwith 10 nmol/l siRNA against mouse Tf or scram-
bled siRNA according to the instructions of the supplier. The
cells were re-transfected after 24 h.
Determination of beta cell death Cell death in MIN-6 cells
was evaluated using a Cell Death ELISAPLUS, detecting en-
richment of cytoplasmic nucleosomes or by propidium iodide
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(PI) staining. Cell death in human islets was studied by insulin
and cleaved caspase-3 staining. To study single beta cells,
islets were mildly dispersed using trypsin. Single islet cells
were cytospinned to microscope slides, fixed in 4% parafor-
maldehyde, blocked, stained using insulin (1/50 dilution) and
cleaved caspase-3 (1/50 dilution) antibodies and analysed un-
der a Zeiss Axiovert 40CFL microscope (Carl Zeiss AG,
Oberkochen, Germany).
Immunoblotting Cells were lysed in SDS sample buffer and
separated by SDS-PAGE. Proteins were transferred to
Immobilon-FL PVDF membranes, blocked in Blok-FL
(Merck Millipore, Billerica, MA, USA) and left overnight at
4°C in Blok-FL with antibodies diluted 1/1,000. Membranes
were washed in Tris-buffered saline containing 0.01% (vol./
vol.) Tween 20 and incubated with secondary antibodies
(1/10,000 dilution). Immunodetection was performed in Od-
yssey Imaging System (LI-COR, Lincoln, NE, USA) and
band intensities quantified by densitometric scanning using
the Odyssey V3.0 software (LI-COR).
Insulin secretion Islets were incubated for 60 min in Krebs-
Ringer bicarbonate HEPES buffer (KRBH) containing
1.67 mmol/l glucose followed by 60 min in KRBH containing
16.7 mmol/l glucose. Media and islets were recovered and
insulin concentration was determined using a human insulin
ELISA. For protocol see [18].
Ethics statement Studies involving human islets were ap-
proved by the local ethical board in Uppsala, Sweden.
Statistics Statistical significances were obtained by compari-
son with the corresponding control using Student’s paired
t test and GraphPad prism software 6.0 (GraphPad software,
San Diego, CA, USA)
Results
Cytokines induce TF expression in human islets andMIN-
6 beta cellsWe first studied the influence of cytokines on TF
expression in islets and beta cells. In human islets and MIN-6
cells, a significant increase in TF mRNA levels (≈ twofold)
was observed following 3 h of exposure to a cytokine mixture
(IL-1β + TNF-α + IFN-γ) when compared with control
(Fig. 1a, b). A further increase (≈ fourfold) was seen after
exposure to cytokines for 6 and 24 h (Fig. 1a, b). This was
paralleled by an induction in TF protein levels in human islets
and MIN-6 cells following 6 and 24 h of cytokine exposure
(Fig. 1c–f). A large pool (61.6±4.9%) of untreated MIN-6
cells stained positive for TF cell surface expression
(Fig. 1g). Cytokine treatment for 6 h increased the number
of TF-positive cells (82.4±6.8%) when compared with
untreated cells (Fig. 1g), indicating that TF total and cell sur-
face expression in beta cells are upregulated in the presence of
cytokines.
TF/FVIIa signalling augments cytokine-induced beta cell
death independently of downstream coagulation We next
studied the effects of FVIIa on cytokine-induced beta cell
death, evaluated by a cell-death ELISA and PI staining.
Treatment of MIN-6 cells with cytokine mixture led to
an increase in cell death (Fig. 2). FVIIa treatment alone
had no significant effect on cell death (Fig. 2). Con-
versely, FVIIa pre-treatment significantly potentiated
cytokine-induced cell death (Fig. 2). Addition of FXa
had no effect on cytokine-induced beta cell death and
the thrombin inhibitor hirudin failed to prevent the po-
tentiation of cytokine-induced beta cell death induced
by FVIIa (Fig. 2a).
We also studied the effects of the individual cytokines IL-
1β, TNF-α and IFN-γ on beta cell death and on TF/FVIIa
signalling. IL-1β treatment alone led to a significant increase
in cell death and TNF-α, albeit not reaching statistical
significance, increased cell death (Fig. 2c). IFN-γ treat-
ment alone did not affect cell viability (Fig. 2c). The
cytokine mixture further potentiated beta cell death when
compared with IL-1β or TNF-α treatment alone. FVIIa
pre-treatment significantly augmented beta cell death in
response to IL-1β or TNF-α alone or to cytokine mix-
ture but failed to promote beta cell death in response to
IFN-γ (Fig. 2c). Moreover, IL-1 Ra partially inhibited
cell death induced by the cytokine mixture in both un-
treated and FVIIa pre-treated cells (Fig. 2c).
Finally, we investigated the effects of FVIIa in primary
human islet cells. Untreated islets or islets treated with cyto-
kine mixture for 72 h were dispersed to generate single islet
cells and then co-stained using insulin and cleaved caspase-3
antibodies. The number of insulin-positive cells varied be-
tween 30% and 80% using five different donor preparations
(Fig. 3). The cytokine mixture induced caspase-3 cleavage in
beta cells when compared with control cells and caspase-3
cleavage was further increased by FVIIa pre-treatment
(Fig. 3b).
TF downregulation blocks the effect of FVIIa on cytokine-
induced beta cell death To determine whether the effects of
FVIIa are dependent on TF/FVIIa, we downregulated TF pro-
tein levels (Fig. 4a, b). FVIIa potentiated cell death induced by
the cytokine mixture in MIN-6 cells transfected with scram-
bled siRNA, when analysed using a cell-death ELISA
(Fig. 4c). Tf siRNA prevented FVIIa-induced potentiation of
cytokine-induced cell death but did not restore cell death to
control levels (Fig. 4c). In addition, we used a TF antibody to
block TF/FVIIa. We observed a decrease in cytokine-induced
cell death after administration of TF antibody alone (Fig. 4d).
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Fig. 1 Cytokines induce TF expression in human islets and MIN-6 cells.
Human islets and MIN-6 cells were left untreated (Control) or treated
with a cytokine mixture of IL-1β + TNF-α + IFN-γ (Cyt.) for the indi-
cated time periods. TFmRNA levels related to RPLP0 in (a) human islets
and (b) MIN-6 cells. Immunoblot and graphs showing TF/GAPDH ratio
using TF and GAPDH antibodies on (c, d) human islets and (e, f) MIN-6
cells. (g) MIN-6 cells were left untreated (Control) or were treated with
cytokine mixture (Cyt.) for 6 h. Cells were incubated with mouse TF
antibody (Ab) and TF cell surface expression was analysed using flow
cytometry detecting forward scatter height (FSC-H) and fluorescence in
fluorescence channel 1 height (FL1-H). Normal goat IgG was used as
isotype control. Results are means ± SEM from four (a–f) or three (g)













































































































































Fig. 2 TF/FVIIa signalling augments cytokine-induced beta cell death
independently of downstream coagulation. MIN-6 cells were pre-treated
with FVIIa (10 nmol/l), FXa (100 nmol/l) or FVIIa+hirudin (10 U/ml) for
6 h, followed by treatment with a cytokine mixture of IL-1β, TNF-α and
IFN-γ (Cyt.) for 72 h. (a) Cell death was quantified using a cell-death
ELISA by measuring absorbance (A405–A490). (b) Cells were stained
with PI and Hoechst 33 258 (HO), ~2,000 cells/group were counted
and the number of PI-positive cells was determined by fluorescence
microscopy. (c) MIN-6 cells were first pre-treated with FVIIa (10 nmol/
l) for 6 h. Indicated groups were then treated with IL-1 Ra (500 ng/ml) for
30 min followed by treatment with individual cytokines or with cytokine
mixture for 72 h. Cell death was quantified using a cell-death ELISA by
measuring absorbance (A405–A490). Results are means ± SEM from four
experiments. *p<0.05 for indicated comparisons, using paired Student’s t
test
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Moreover, TF antibody counteracted the potentiation of cyto-
kines induced by FVIIa but failed to restore cell death to
control levels (Fig. 4d).
TF/FVIIa signalling promotes cytokine-induced beta cell
death via activation of the stress kinase JNK To identify the
mechanisms behind the effects of TF/FVIIa on cytokine-
induced beta cell death, we studied the consequences of cyto-
kine and FVIIa treatment on mitogen-activated protein kinase
(MAPK) activation. Treatment with cytokines resulted in in-
creased phosphorylation of p38, ERK and JNK in islets and
MIN-6 beta cells (Fig. 5). FVIIa did not alter ERK or p38 phos-
phorylation in response to cytokines, but augmented cytokine-
induced JNK phosphorylation (Fig. 5), an event that was
abolished by Tf siRNA (Fig. 6b). FVIIa did not affect phosphor-
ylation of p38, ERK or JNK at basal conditions (Fig. 5).
We also studied the contribution of individual cytokines to
JNK activation. IL-1β and, to a lesser extent, TNF-α individ-
ually promoted JNK phosphorylation inMIN-6 cells, whereas
IFN-γ did not (Fig. 6a). The cytokine mixture further in-
creased JNK phosphorylation when compared with IL-1β or

























































Fig. 3 FVIIa promotes cytokine-induced caspase-3 cleavage in primary
human beta cells. (a) Untreated or FVIIa pre-treated (10 nmol/l, 6 h)
human islets were stimulated with a cytokine mixture of IL-1β, TNF-α
and IFN-γ (Cyt.) for 72 h, then mildly dispersed using trypsin to generate
single islet cells. Cells were stained with DAPI (blue), insulin antibody
(red) and cleaved caspase-3 antibody (green) and visualised by
fluorescence microscopy. Islets from five different donors were used
and images show results from one representative donor. Scale bar,
50 μm. (b) Cells (~2,000/group) were counted and the number of cells
double-positive for insulin and cleaved caspase-3 are depicted in the
graph. Results are means ± SEM from five experiments. *p<0.05 for





















































































































































Fig. 4 TF downregulation blocks the effect of FVIIa on cytokine-in-
duced beta cell death. (a, b) MIN-6 cells were transfected with scrambled
(Scr.) or Tf siRNA. At 48 or 72 h post transfection, cells were subjected to
immunoblotting using TF and GAPDH antibodies. (c) At 48 h after
siRNA transfection, MIN-6 cells were pre-treated with FVIIa (10 nmol/
l) for 6 h followed by treatment with a cytokine mixture of IL-1β, TNF-α
and IFN-γ (Cyt.) for 72 h. Cell death was quantified using a cell-death
ELISA measuring absorbance (A405–A490). (d) MIN-6 cells were cul-
tured in the absence or presence of TF antibody (Ab) 4515 (100 μg/ml,
1 h). Cells were left untreated or were treated with FVIIa (10 nmol/l) for
6 h and then cytokine mixture for 72 h. Cell death was quantified using a
cell-death ELISA measuring absorbance (A405–A490). Results are means
± SEM from three (a, b) or four (c, d) individual experiments. *p<0.05
for indicated comparisons, using paired Student’s t test
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JNK activation in response to IL-1β, TNF-α and the cytokine
mixture (Fig. 6a).
To determine the functional importance of TF/FVIIa-
mediated JNK activation in response to cytokines, we next
studied how MAPK activity affected cytokine-induced beta
cell death. MIN-6 beta cells were cultured in the absence or
presence of inhibitors of p38, MEK1/2 (ERK) or JNK prior to
addition of FVIIa and cytokine mixture. Inhibition of p38,
ERK or JNK alone or in combination with FVIIa did not affect
basal beta cell death whereas all inhibitors mitigated cytokine-
induced beta cell death (Fig. 6c). The effect of FVIIa on
cytokine-induced beta cell death was not changed by inhibi-
tion of p38 or ERK but was abolished in the presence of JNK
inhibition, suggesting that TF/FVIIa mediates beta cell death
in response to cytokines by mechanisms involving activation
of the stress kinase JNK (Fig. 6c).
TF/FVIIa signalling impairs glucose-stimulated insulin se-
cretion from human pancreatic islets To find out how TF/
FVIIa signalling influences the function of beta cells, we mea-
sured glucose-stimulated insulin secretion (GSIS) from hu-
man islets using ELISA. When normalised to islet DNA con-
tent, islets pre-treated with FVIIa secreted a similar amount of
insulin to that secreted by control islets when cultured in a
low-glucose concentration (Fig. 7a). However, when cultured
in an increased concentration of glucose, there was an im-
paired insulin secretion in islets treated with FVIIa when com-
pared with control islets (Fig. 7a). Furthermore, the inhibition
of GSIS by FVIIa was counteracted by TF antibody 10H10.
Islet insulin content was similar in FVIIa-treated and control
islets (Fig. 7b).
Discussion
We herein report that cytokines promote TF expression in
islets and beta cells and that TF/FVIIa signalling impairs islet



















































































































































































































































Fig. 5 TF/FVIIa signalling promotes cytokine-induced activation of the
stress kinase JNK. Human islets (a–c) and MIN-6 cells (d–f) were either
left untreated (Control) or pre-treated with FVIIa (50 nmol/l for human
islets and 10 nmol/l for MIN-6 cells) for 30 min. Some groups were
treated with a cytokine mixture of IL-1β, TNF-α and IFN-γ (Cyt.) for
15 min. Islets and cells were analysed by immunoblotting using antibod-
ies against total and phosphorylated forms of ERK, p38 and JNK. The
fold increase vs control was determined by calculating the ratio between
phosphorylated and total band intensities. The two forms of JNK and
ERK were quantified as one band. When phospho-p38 and phospho-
JNK bands were undetectable in control groups, the background intensity
was used for quantification. Results are means ± SEM from four inde-
pendent experiments. *p<0.05 for the indicated comparisons, using
paired Student’s t test
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cytokines. Our findings provide evidence for and mechanistic
insight into how TF/FVIIa signalling could contribute to beta
cell destruction and diabetes.
Inflammation is believed to be a key feature in the patho-
genesis of diabetes and cytokines are known to contribute to
the failure and death of beta cells [2]. Since TF/FVIIa, via
coagulation or intracellular signalling can result in inflamma-
tory responses [4, 19], we investigated in vitro its role in
cytokine-induced beta cell death, in order to understand the
molecular mechanism involved in its action. This is relevant
since several clinical observations support a role for TF/FVII
in diabetes. Plasma levels of TF antigen, TF activity, TF-
containing microparticles and FVIIa are elevated in patients
with type 1 and type 2 diabetes when compared with control
individuals [10–15] and glucose-lowering drugs such as met-
formin and exenatide downregulate TF expression [20, 21].
Our data suggest that FVIIa promotes cytokine-induced
beta cell death by binding to TF. TF downregulation and a
TF antibody abolished the effect of FVIIa on cytokine-
induced beta cell death and it is therefore unlikely that the
effect is mediated through a TF-independent mechanism. We
noted that the TF antibody provided protection against
cytokine-induced beta cell death even in the absence of FVIIa
stimulation. The reason for this remains unclear but it has been
reported that cancer cells can express FVII/FVIIa [22]. One















































































































































































































































Fig. 6 TF/FVIIa-mediated JNK activation promotes cytokine-induced
beta cell death. (a) MIN-6 cells were pre-treated with FVIIa (10 nmol/l)
for 6 h followed by treatment with individual cytokines or a cytokine
mixture of IL-1β, TNF-α and IFN-γ (Cyt.) for 15 min. Cells were then
lysed and subjected to immunoblotting using phospho- and total JNK
antibodies. (b) MIN-6 cells were transfected with scrambled (Scr.) siRNA
or Tf siRNA. At 72 h post transfection cells were stimulated with cytokine
mixture for 15 min, lysed and subjected to immunoblotting using TF and
JNK antibodies. (c) MIN-6 cells were pre-treated with FVIIa (10 nmol/l)
for 6 h followed by treatment with cytokine mixture for 72 h. Thirty
minutes before the addition of FVIIa, p38 inhibitor SB203580
(10 μmol/l), MEK1/2 inhibitor PD98059 (10 μmol/l) and JNK inhibitor
SP600125 (10μmol/l) were added to the indicated groups. Cell death was
quantified using a cell-death ELISA measuring absorbance (A405–A490).
Results are means ± SD from three (a, b) or four (c) individual experi-
ments. *p<0.05 for indicated comparisons, using paired Student’s t test
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produce FVII/FVIIa. TF/FVIIa is known to mediate cellular
signalling that is uncoupled to FXa or thrombin generation
[23]. Consistent with this, the effect of TF/FVIIa on
cytokine-induced beta cell death was found to be independent
of downstream coagulation, since addition of FXa did not
affect beta cell death in response to cytokines and the throm-
bin inhibitor hirudin failed to abrogate the effect of FVIIa.
It appears that TF/FVIIa signalling affects both the IL-1β
and the TNF-α pathway. FVIIa stimulation alone did not af-
fect basal cell death whereas it augmented beta cell death
when combined with IL-1β or TNF-α individually or with
cytokine mixture. Interestingly, TF has been associated with
anti-apoptotic effects in several non-islet cells [23]. With
regards to this, we did note that cells treated with TfsiRNA,
under basal conditions, showed a small increase in cell death
compared with control cells. It might therefore be that TF
promotes survival of unstressed beta cells but that it mediates
cell death when the beta cells are challenged with inflamma-
tory stress and FVIIa binding.
Our results support the notion that cytokines have cooper-
ative effects on beta cells. We found that treatment with cyto-
kine mixture further increased beta cell death when compared
with the effects of IL-1β or TNF-α alone. Moreover, IL-1 Ra
only partially blocked cell death induced by the cytokine mix-
ture. In our experiments, IFN-γ alone did not induce beta cell
death. This is in agreement with data showing that IFN-γ by
itself is not detrimental to beta cells but when combined with
IL-1β or TNF-α it promotes beta cell death [24].
We propose JNK to be the main mediator of the TF/FVIIa
signalling effect. It is known that p38 and JNK mediate beta
cell death in vitro in response to cytokines and that this event
can be blocked by inhibition of p38 or JNK [25–28]. Treat-
ment with the cytokine mixture led to phosphorylation of p38,
ERK and JNK. FVIIa pre-treatment did not affect cytokine-
induced ERK and p38 phosphorylation but augmented
cytokine-induced JNK phosphorylation. Also, IL-1β and
TNF-α individually promoted JNK phosphorylation in
MIN-6 cells and maximal JNK activity was observed in cells
treated with cytokinemixture, indicating a synergistic effect of
cytokines on beta cells. Moreover, JNK inhibition abolished
the effect of FVIIa on cytokine-induced beta cell death, indi-
cating that JNK activation is necessary for the effects of TF/
FVIIa on cytokine-induced beta cell death. JNK activation
also contributes to insulin resistance and JNK activity in mac-
rophages is necessary for the development of diet-induced
insulin resistance [29–32]. Intriguingly, TF/FVIIa signalling
promotes high-fat diet-induced obesity, adipose tissue inflam-
mation and insulin resistance in mice [6]. TF/FVIIa-induced
JNK activity could therefore not only promote beta cell death
in response to cytokines but also contribute to peripheral in-
sulin resistance.
We also report that TF/FVIIa signalling impairs beta cell
function. Since FVIIa-treated islets and control islets
contained a similar amount of insulin, the effect of TF/FVIIa
on GSIS cannot be accounted for by differences in insulin
storage. Instead, our results favour the view that TF/FVIIa
signalling somehow perturbs the stimulus–secretion coupling
process. In these experiments, the TF antibody 10H10
blocked the detrimental effects of FVIIa on GSIS. Given that
the 10H10 antibody mainly targets TF/FVIIa signalling by
inhibition of protease-activated receptor 2 (PAR-2) cleavage,
the effect of TF/FVIIa on GSIS is likely to be mediated via a
PAR-2-dependent pathway [33]. Consistent with this view,
Regard et al [34] and Lim et al [35] showed that PAR-2 acti-
vation leads to inhibition of GSIS from MIN-6 beta cells.
Beta cells in vivo are exposed to a variety of cytokines. We
demonstrate that TF expression in islets and beta cells is in-
duced by a combination of the cytokines IL-1β, TNF-α and
IFN-γ. This is in line with studies demonstrating that cyto-
kines promote TF expression in several non-islet cell types
[36–38]. The induction of TF is probably mediated by nuclear
factor κ-light-chain enhancer of activated B cells (NF-κβ). IL-
1β and TNF-α promote NF-κβ activation in beta cells and TF
expression can be rapidly induced by activation of NF-κβ in
other cell types [39–41].
The mechanisms by which TF/FVIIa promotes JNK phos-
phorylation in response to cytokines in beta cells remain un-
known but may involve activation of PAR-2. PAR-2 signal-
ling mediates inflammatory responses in various cell types
and can result in JNK activation in keratinocytes [42]. JNK
activity is regulated by upstream MAP3Ks and different
MAP3Ks, such as apoptosis signal-regulating kinase 1 and
MAPK kinase kinase 1, promote JNK activation in a cell
type- and stimulus-specific manner [41]. Future studies will
hopefully delineate the mechanism by which TF/FVIIa pro-













































































Fig. 7 TF/FVIIa impairs GSIS from human pancreatic islets. (a) Human
islets in groups of 10 in triplicates were either left untreated or treated with
FVIIa (50 μmol/l, 3 h). To some groups TF antibody 10H10 (TF Ab)
(50 μg/ml) was added 30 min before the FVIIa. Insulin release from islets
to the culture media in response to low glucose (1.67 mmol/l, 1 h) and
high glucose (16.7 mmol/l, 1 h) was quantified using ELISA. Values are
normalised to the amount of DNA/sample. Results are mean values from
triplicates of islets from three different donors. *p<0.05 vs high-glucose
control, using paired Student’s t test. (b) Islets from (a) were recovered
and insulin content was determined using ELISA
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To conclude, we provide evidence that TF expression in
islets and beta cells is induced by cytokines and propose that
TF/FVIIa signalling promotes cytokine-induced beta cell
death and inhibits islet function. Inhibiting TF/FVIIa signal-
ling (e.g. by using a TF blocking antibody that has minimal
effect on coagulation) could be a novel way to promote beta
cell survival and function.
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